Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. trimmed its holdings in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 7.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,912,140 shares of the biotechnology company's stock after selling 1,235,269 shares during the period. Baillie Gifford & Co. owned about 1.60% of Adaptimmune Therapeutics worth $12,618,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ADAP. Two Sigma Investments LP purchased a new stake in shares of Adaptimmune Therapeutics during the fourth quarter worth about $33,000. UBS Group AG boosted its holdings in shares of Adaptimmune Therapeutics by 1,090.8% during the fourth quarter. UBS Group AG now owns 23,625 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 21,641 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Adaptimmune Therapeutics by 56.4% during the second quarter. Goldman Sachs Group Inc. now owns 48,077 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 17,332 shares during the period. Barclays PLC purchased a new stake in shares of Adaptimmune Therapeutics during the second quarter worth about $46,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Adaptimmune Therapeutics during the fourth quarter worth about $48,000. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Adaptimmune Therapeutics in a report on Friday, December 29th. They issued a "hold" rating for the company.

Adaptimmune Therapeutics Trading Up 1.6 %

ADAP stock traded up $0.02 on Thursday, hitting $1.29. The company had a trading volume of 877,248 shares, compared to its average volume of 1,793,172. Adaptimmune Therapeutics plc has a 12-month low of $0.42 and a 12-month high of $2.05. The stock's 50-day simple moving average is $1.42 and its 200 day simple moving average is $0.91. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -2.35 and a beta of 2.39.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last issued its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.12). Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative return on equity of 155.39%. The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $4.80 million. Research analysts forecast that Adaptimmune Therapeutics plc will post -0.44 earnings per share for the current year.

Adaptimmune Therapeutics Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.